{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n MAB21L4, also known as C2orf54, has emerged as an important mediator of transforming growth factor‐β (TGF‐β) signaling in differentiated epidermal keratinocytes. In this cellular context, TGF‐β robustly induces MAB21L4 expression, which in turn acts to amplify TGF‐β–dependent gene expression. Mechanistically, MAB21L4 localizes predominantly to the cytosol, where it interacts with Smad3 as well as the transcriptional corepressor c‑Ski. This interaction appears to counteract c‑Ski’s inhibitory influence on transcription, thereby facilitating the accumulation of active histone marks (H3K27ac) near Smad3 binding sites and promoting the expression of target genes such as involucrin – a key barrier protein."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In a separate study focusing on esophageal squamous cell carcinoma (ESCC), MAB21L4 (listed under its alternate designation C2orf54) was identified among a panel of down‐regulated genes that are differentially expressed between tumor and normal tissues. Although the precise mechanistic contribution in ESCC remains to be fully elucidated, its reduced expression in this setting underscores its potential utility as a biomarker for early detection and prognostic stratification in ESCC."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Tomohiro Ogami, Yusuke Tamura, Kim Toss, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MAB21L4 regulates the TGF-β-induced expression of target genes in epidermal keratinocytes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biochem (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/jb/mvab141"}], "href": "https://doi.org/10.1093/jb/mvab141"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34908107"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34908107"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Kubra Karagoz, Heather L Lehman, Douglas B Stairs, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Proteomic and Metabolic Signatures of Esophageal Squamous Cell Carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Curr Cancer Drug Targets (2016)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26845434"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26845434"}]}]}]}